A med spa valuation multiple is meaningful only when the earnings definition, business size, operating risk, and deal consideration are comparable. Owner-operated practices may be evaluated on SDE; managed practices are often discussed using adjusted EBITDA. Published ranges are starting evidence, not a price guarantee. Normalize earnings and examine transaction terms before applying them.
What does a valuation multiple actually measure?
A multiple relates an agreed value measure to an earnings measure. The numerator might be enterprise value, asset consideration, or reported transaction price. The denominator might be trailing earnings, forecast earnings, SDE, or adjusted EBITDA. Two quotations that both say five times can describe materially different economics.
Enterprise value is a measure of the operating business value before the transaction’s specific bridge to equity consideration. Exact debt, cash, and working-capital treatment must be defined in the offer. Do not assume that a website’s sale-price statistic uses the same definition as a buyer’s enterprise-value proposal.
Ask the person quoting a multiple to write the formula. Specify the earnings period, adjustments, included assets, excluded cash, assumed debt, and contingent consideration. This simple step often reveals that an apparent pricing disagreement is actually a disagreement about what is being measured.
How are SDE and adjusted EBITDA different?
SDE commonly presents the earnings benefit available to a working owner, with owner compensation and certain discretionary expenses added back under a defined methodology. Adjusted EBITDA aims to describe operating earnings before interest, taxes, depreciation, and amortization after appropriate normalization. Neither measure is useful without the underlying reconciliation.
A buyer who needs to hire the seller’s replacement cannot treat all owner compensation as free cash. Identify clinical production, management, and administrative tasks separately. The replacement requirement may differ between a clinician buyer working in the practice and a financial buyer adding employees.
| Item | Amount |
|---|---|
| Reported EBITDA | $210,000 |
| Owner compensation added back | +$185,000 |
| Other supported discretionary items | +$15,000 |
| Illustrative SDE | $410,000 |
| Replacement clinical and management labor | −$230,000 |
| Illustrative managed earnings | $180,000 |
What do published med spa ranges actually tell us?
Tommy Newton’s May 15, 2026 AmSpa retrospective described 2025 EBITDA ranges by revenue scale: 3–6 times below $4 million revenue; 5–8 times at $4–20 million; and 7–12 times above $20 million for larger regional platforms. These are that advisor’s observations, not this site’s independent transaction survey.
The article does not provide a transaction-by-transaction sample, standardized adjustment policy, or a statistical confidence interval. Its ranges can frame questions about scale and management depth, but cannot establish the value of a particular practice. Do not extrapolate the platform band to an owner-dependent single location.
When presenting any range to a seller, retain the source date and basis beside it. Clarify whether recent closed comparables support the proposed point within the range. A current publication discussing last year’s deals is not the same as verified pricing for today’s exact target.
Why can broad spa benchmarks mislead a med spa owner?
BizBuySell’s health and beauty spa benchmarks include beauty spas, day spas, and medical spas, with owner earnings used in the analysis. That mixed population is useful context for small-business transactions. It is not a clean sample of physician-supervised aesthetics acquisitions or a platform EBITDA dataset.
A large spread between a marketplace earnings multiple and an institutional EBITDA quotation can reflect different owners, earnings definitions, business sizes, transaction structures, and reporting practices. It does not by itself prove that one buyer is unfair or one source is wrong.
Check listing prices separately from completed sales. An asking-price multiple describes seller expectations; a closed-sale multiple describes a reported transaction. Neither tells you how much cash was delivered at closing unless the underlying payment terms are disclosed. Avoid combining medians from separate columns to fabricate a representative transaction.
Which operating facts change a buyer’s willingness to pay?
Begin with earnings durability: provider retention, patient recurrence, service-level contribution, management independence, and clean reporting. Then examine future cash requirements, including device service and replacement, working capital, membership servicing, and necessary staffing. Revenue growth can coexist with falling cash generation.
Memberships deserve evidence rather than an automatic premium. Demonstrate collection success, retention cohorts, contribution after promised benefits, and unused-credit obligations. An injectables-led model also needs legitimate product sourcing and stable clinical coverage. A device-heavy model may support strong cash flow when utilization and maintenance economics are sound.
These are underwriting considerations, not a universal scoring formula. Show the fact, the mechanism affecting cash or risk, and the valuation consequence you propose. A buyer should be able to explain why a particular risk changes earnings, the multiple, a contractual protection, or more than one element without counting it twice.
How can you use a sensitivity table responsibly?
Build a sensitivity using independently supported earnings and explicitly hypothetical multiples. The point is to show how assumptions interact, not to disguise a chosen asking price as market evidence. Keep the ranges narrow enough to reflect questions the owner can actually resolve.
| Normalized EBITDA | At assumed 4× | At assumed 5× |
|---|---|---|
| $250,000 | $1,000,000 | $1,250,000 |
| $325,000 | $1,300,000 | $1,625,000 |
The difference between $250,000 and $325,000 at the same five-times assumption is $375,000. That may make verifying earnings more consequential than negotiating a small multiple increase. Have the valuation advisor explain which row is supportable and why, then test whether financing and buyer demand support the selected column.
How do financing and structure change the seller’s outcome?
A financed buyer must repay debt from available cash. SBA’s 7(a) overview describes ownership changes as an eligible use while retaining creditworthiness and repayment requirements. A stated price that cannot be financed under the actual operating plan may fail even when an industry range appears to support it.
For a platform proposal, separate cash, rollover equity, earnout, seller note, and escrow. Ask who controls the future earnings calculation, whether additional capital can dilute retained equity, and which events trigger payment. The headline multiple can include amounts that are uncertain or unavailable for years.
Tax treatment also affects proceeds. The IRS business-sale guidance explains that asset categories can produce different gains and tax treatment. Obtain a CPA model using actual basis, entity structure, allocation, and payment timing. Do not multiply enterprise value by a generic after-tax percentage.
How do you evaluate a comparable transaction that is not fully disclosed?
Request the information needed to use it: closing date, practice model, revenue and earnings period, adjustment method, ownership dependence, included assets, and payment components. Where terms remain confidential, ask the advisor to describe the limits of the comparison without revealing another client’s private information.
An undisclosed price cannot substantiate a precise multiple. A publicly announced acquisition can demonstrate buyer activity while offering no usable pricing evidence. Keep those facts separate in the valuation memorandum. When the comparable set is weak, use a broader reasoned range and place more weight on the practice’s verified earnings, cash needs, and executable offers.
What should an owner request in a defensible valuation discussion?
Ask for an earnings bridge, a buyer-specific operating model, relevant completed comparables where available, a reasoned range, and an offer-to-proceeds analysis. Require clear labels separating reported facts, advisor judgments, and illustrative assumptions. A narrow number without that evidence is less useful than a transparent range.
- Agree the valuation date and transaction definition.
- Reconcile SDE and EBITDA with replacement labor.
- Review comparable populations and payment terms.
- Test earnings durability and capital needs.
- Translate enterprise value into expected seller proceeds.
Use the valuation hub for the full earnings-to-proceeds context, seller roadmap for process preparation, and membership analysis for prepaid obligations. The best next step is improving the evidence behind the price, rather than searching for the highest unsupported multiple.
What else do owners and buyers ask?
Is there one normal multiple for every med spa?
No. The earnings basis, provider dependence, management, scale, growth quality, capital requirements, geography, and payment structure can differ substantially. Published ranges can orient a discussion when their populations are understood. A credible valuation needs a reconciled earnings measure and comparable transaction evidence suited to the business being sold.
Can I apply an EBITDA multiple to my SDE?
Only after reconciling the measures and determining the labor needed under the buyer’s plan. SDE may include compensation for an owner who performs essential clinical or management work. Using an EBITDA multiple without deducting appropriate replacement cost can overstate the earnings a managed buyer will actually retain.
Does a higher multiple always mean a better offer?
No. One proposal may include rollover equity or contingent payments while another provides more cash at closing. Debt payoff, working capital, employment obligations, indemnities, and taxes also affect value to the seller. Compare a complete proceeds bridge and the risk of each payment component, not the quoted multiple alone.
Should I wait until my med spa reaches platform size?
Consider the additional capital, management, execution risk, and time required before assuming expansion improves your exit. A platform valuation requires more than additional addresses. Model the likely retained earnings and investment needed, then compare the result with a sale of the current business under realistic buyer and transition assumptions.
Which sources support this guide?
Sources were checked during research. Regulations, lender policies, and market conditions can change. Use the linked primary material and your advisors to confirm applicability.
- Med Spa M&A and Private Sales: A Look Back at 2025—and What Lies Ahead — American Med Spa Association; Tommy Newton, Xite
- Health and beauty spa valuation benchmarks — BizBuySell
- 7(a) loans — U.S. Small Business Administration
- Sale of a business — Internal Revenue Service
Educational analysis prepared with AI-assisted research for The Med Spa Broker. “Last reviewed” records the source and editorial check date; it does not imply review by an attorney, clinician, or independent appraiser. Read our editorial standards.